Drug Detail

Information about Gleevec + Avastin

Generic Name
Imatinib + Bevacizumab
STI571 + bevacizumab
Brand Name (US)
Gleevec + Avastin
Novartis and Genentech
Drug Type
Tyrosine Kinase Inhibitor and Monoclonal antibody
Oral (imatinib) Intravenous (bevacizumab)
Approval Status
Both are approved. A trial of this combination in GIST was terminated due to lack of recruitment.
Overall Strategy
KIT Protein Based
Block KIT Block tumor blood vessel growth
Drug Category
KIT/PDGFRA inhibitor+ VEGF inhibitor (antibody)

Imatinib (Gleevec) is a potent KIT inhibitor and is the approved front line drug for GIST.
Avastin is an approved monoclonal antibody that targets the VEGF pathway. It has been shown to extend survival in colon cancer.
It is hoped that the combination will provide more a more potent antiangiogenic effect than either drug alone. In addition, imatinib provides a potent direct antitumor effect against GIST tumors through it's inhibition of KIT.